Web Access Research Portal

Researcher: Palmer, AJ (Professor Andrew Palmer)

Fields of Research

Health Economics
Epidemiology
Public Health and Health Services
Central Nervous System
Aged Health Care
Cardiology (incl. Cardiovascular Diseases)
Health and Community Services
Residential Client Care
Rheumatology and Arthritis
Primary Health Care
Health Promotion
Complementary and Alternative Medicine
Clinical Sciences
Endocrinology
Nephrology and Urology
Cardiorespiratory Medicine and Haematology
Neurology and Neuromuscular Diseases
Aged Care Nursing
Surgery
Paediatrics
Autonomic Nervous System
Gastroenterology and Hepatology
Health, Clinical and Counselling Psychology
Health Information Systems (incl. Surveillance)
Health Care Administration
Infectious Diseases
Preventive Medicine
Psychiatry (incl. Psychotherapy)
Sports Medicine
Respiratory Diseases
Haematology
Environmental and Occupational Health and Safety
Geriatrics and Gerontology
Sociology
Applied Sociology, Program Evaluation and Social Impact Assessment
Medical and Health Sciences
Mental Health
Nursing
Architectural Science and Technology (incl. Acoustics, Lighting, Structure and Ecologically Sustainable Design)
Rehabilitation and Therapy (excl. Physiotherapy)
Emergency Medicine
Allergy
Clinical Nursing: Primary (Preventative)
Medicine, Nursing and Health Curriculum and Pedagogy
Peripheral Nervous System
Health Policy
Aboriginal and Torres Strait Islander Health

Research Objectives

Health Policy Economic Outcomes
Evaluation of Health Outcomes
Nervous System and Disorders
Injury Control
Diabetes
Health Policy Evaluation
Blood Disorders
Health and Support Services
Public Health (excl. Specific Population Health)
Cardiovascular System and Diseases
Health Related to Ageing
Skeletal System and Disorders (incl. Arthritis)
Health Education and Promotion
Preventive Medicine
Specific Population Health (excl. Indigenous Health)
Behaviour and Health
Nursing
Mental Health
Urogenital System and Disorders
Health
Health Status (e.g. Indicators of Well-Being)
Respiratory System and Diseases (incl. Asthma)
Neurodegenerative Disorders Related to Ageing
Clinical Health (Organs, Diseases and Abnormal Conditions)
Infectious Diseases
Occupational Health
Allied Health Therapies (excl. Mental Health Services)
Disease Distribution and Transmission (incl. Surveillance and Response)
Aboriginal and Torres Strait Islander Health - Health Status and Outcomes
Surgical Methods and Procedures
Digestive System Disorders
Substance Abuse
Carer Health
Education and Training Systems Policies and Development
Ageing and Older People
Disability and Functional Capacity
Cancer and Related Disorders
Road Safety
Residential Construction Design
Fixed Line Telephone Networks and Services
Rural Health
Immune System and Allergy
Palliative Care

Career Best Publications

Research Publications

A critical review of pharmacoeconomic studies of acamprosate; Alcohol and Alcoholism
A decision tree model for the implementation of a safety strategy in the horse-racing industry; Injury Prevention
A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension; Current Medical Research and Opinion
A head-to-head comparison of the EQ-5D-5L and AQoL-8D multi-attribute utility instruments in patients who have previously undergone bariatric surgery; The Patient
A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA; Nephrology, Dialysis and Transplantation
A health economic model to determine the long-term costs and clinical outcomes of raising low HDL-cholesterol in the prevention of coronary heart disease; Current Medical Research and Opinion
A meta-analysis of the relative risk of mortality for type 1 diabetes patients compared to the general population: exploring temporal changes in relative mortality; PL o S One
A multivariate logistic regression equation to screen for diabetes: response to Tabaei and Herman; Diabetes Care
A novel method for calculating prevalence of multiple sclerosis in Australia; Multiple Sclerosis
A systematic review and meta-analysis of utility-based quality of life for osteoporosis-related conditions; Osteoporosis International
A systematic review and narrative synthesis of health economic studies conducted for hereditary haemochromatosis; Applied Health Economics and Health Policy
A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures; Osteoporosis International
Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting; Current Medical Research and Opinion
Accident rates amongst regular bicycle riders in Tasmania, Australia; Accident Analysis and Prevention
An Asian Regional Analysis of Cost-Effectiveness of Early Irbesartan Treatment versus Conventional Antihypertensive, Late Amlodipine, and Late Irbesartan Treatments in Patients with Type 2 Diabetes, Hypertension, and Nephropathy; Value in Health
An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK; Current Medical Research and Opinion
An Economic Evaluation of Irbesartan in the Treatment of Patients with Type 2 Diabetes, Hypertension and Nephropathy: Cost-Effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French Settings; Nephrology, Dialysis and Transplantation
An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting; Journal of Human Hypertension
An exploratory study of long-term publicly waitlisted bariatric surgery patients’ quality of life before and 1 year after bariatric surgery, and considerations for healthcare planners; PharmacoEconomics - Open
Applying some UK Prospective Diabetes Study results to Switzerland: The cost-effectiveness of intensive glycemic control with metformin versus conventional control in overweight patients with type 2 diabetes; Schweizerische Medizinische Wochenschrift
Assessing equity in benefit distribution of government health subsidy in 2012 across East China: benefit incidence analysis; International Journal for Equity in Health
Assessing possible selection bias in a national voluntary MS longitudinal study in Australia; Multiple Sclerosis
Assessment and management of chronic respiratory conditions in frail older adults
Australian insurance costs of jockeys injured in a race-day fall; Occupational Medicine
Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naive type 2 diabetes patients: modelling the long-term health economic implications in a Swedish setting; International Journal of Clinical Practice
Characteristics of, and insurance payments for, injuries to cyclists in Tasmania, 1990-2010; Accident Analysis & Prevention
Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy; Deutsche Medizinische Wochenschrift
Commentary: Intensive glucose control is more costly than conventional treatment but also has more benefits for people with type-2 diabetes; Evidence - Based Healthcare and Public Health
Comments on Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting; Current Medical Research and Opinion
Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes; Current Medical Research and Opinion
Computer modeling of diabetes and its complications - A report on the Fourth Mount Hood Challenge Meeting; Diabetes Care
Computer modeling of diabetes and its complications: a report on the fifth Mount Hood challenge meeting; Value in Health
Construct validity of SF-6D health state utility values in an employed population; Quality of Life Research
Continuous Subcutaneous Insulin Infusion versus Multiple Daily Injections of Insulin: Economic Comparison in Adult and Adolescent Type 1 Diabetes Mellitus in Australia; Pharmacoeconomics
Cost and clinical implications of diabetes prevention in an Australian setting: A long-term modeling analysis; Primary Care Diabetes
Cost-consequence analysis in a French setting of screening and optimal treatment of nephropathy in hypertensive patients with type 2 diabetes; Diabetes & Metabolism
Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand; Value in Health
Cost-effectiveness of basal insulin from a US health system perspective: Comparative analyses of detemir, glargine, and NPH; Advances in Therapy: The International Journal of Drug, Device and Diagnostic Research
Cost-effectiveness of CSII - Response (Response to the letter by Philip Home); Diabetic Medicine
Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials; Current Medical Research and Opinion
Cost-effectiveness of diabetes case management for low-income populations; Health Services Research
Cost-effectiveness of different population screening strategies for hereditary haemochromatosis in Australia; Applied Health Economics and Health Policy
Cost-Effectiveness of Early Irbesartan Treatment Versus Control (Standard Antihypertensive Medications Excluding ACE Inhibitors, Other Angiotensin-2 Receptor Antagonists, and Dihydropyridine Calcium Channel Blockers) or Late Irbesartan Treatment in Patients With Type 2 Diabetes, Hypertension, and Renal Disease; Diabetes Care
Cost-Effectiveness of Early versus Late Cinacalcet Treatment in Addition to Standard Care for Secondary Renal Hyperparathyroidism in the USA; Value in Health
Cost-effectiveness of Ibersartan in type II diabetic nephropathy with hypertension. A Spanish perspective; Nefrologia
Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study; Current Medical Research and Opinion
Cost-effectiveness of Intensified versus conventional multifactorial intervention in type 2 diabetes: Results and projections from the Steno-2 study; Diabetes Care
Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective; Clinical Therapeutics: The International, Peer-Reviewed Journal of Drug Therapy
Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies; Nephrology, Dialysis and Transplantation
Cost-effectiveness of raloxifene in the treatment of osteoporosis in Chinese postmenopausal women: impact of medication persistence and adherence; Patient Preference and Adherence
Cost-effectiveness of the Concord Minimal Trauma Fracture Liaison service, a prospective, controlled fracture prevention study; Osteoporosis International
Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes; Current Medical Research and Opinion
Cost-utility analysis of cinacalcet in addition to standard of care in the UK; Nephrology, Dialysis and Transplantation
Costs associated with hereditary haemochromatosis in Australia: a cost-of-illness study; Australian Health Review
Counting the cost of dementia-related hospital admissions: a regional investigation; Australasian Journal on Ageing
Counting the costs of overweight and obesity: modeling clinical and cost outcomes; Current Medical Research and Opinion
CU3 – Life Expectancy, Quality-Adjusted Life Years, and Total Lifetime Costs for Australian People with Multiple Sclerosis; Value in Health
Deleterious effects of increased body weight associated with intensive insulin therapy for type 1 diabetes: increased blood pressure and worsened lipid profile partially negate improvements in life expectancy; Current Medical Research and Opinion
Dementia tsunami in aged care: can students improve residents' quality of life?; The 46th Australian Association of Gerontology National Conference
Depression in working adults: comparing the costs and health outcomes of working when ill; PLoS One
Development of the Workplace Health Savings Calculator: a practical tool to measure economic impact from reduced absenteeism and staff turnover in workplace health promotion; BMC Research Notes
Diverse approaches to the health economic evaluation of bariatric surgery: a comprehensive systematic review; Obesity Reviews
Economic and clinical impact of alternative disease management strategies for secondary prevention in type 2 diabetes in the Swiss setting ; Swiss Medical Weekly
Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada; Pharmacoeconomics
Economic Impact of Multiple Sclerosis in 2010: Australian MS Longitudinal Study
Economic implications of the Total Ischemic Burden Bisoprolol Study (TIBBS) follow-up; Journal of Medical Economics
Efficacy and safety of low molecular weight heparin, unfractionated heparin and warfarin for thromboembolism prophylaxis in orthopaedic surgery: A meta-analysis of randomised clinical trials; Haemostasis
Establishing benchmark EQ-5D-3L population health state utilities and identifying their correlates in Gansu Province, China; Quality of Life Research
Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus; Value in Health
Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes; Advances in Therapy: The International Journal of Drug, Device and Diagnostic Research
Evaluating the Long-Term Cost-Effectiveness of Liraglutide Versus Exenatide BID in Patients With Type 2 Diabetes Who Fail to Improve With Oral Antidiabetic Agents; Clinical Therapeutics: The International, Peer-Reviewed Journal of Drug Therapy
Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes; Current Medical Research and Opinion
General Practice After Hours Practice Funding: 2014-15 Funding Model
General practice after-hours incentive funding: a rationale for change; Medical Journal of Australia
Gesundheitsoekonomische Auswirkungen der Algodystrophie unter Einbezug von Calcitonin [Health economic effects of calcitonin on algodystrophy]; Managed Care (Switzerland)
Guidelines for computer modeling of diabetes and its complications; Diabetes Care
Has equity in government subsidy on healthcare improved in China? Evidence from the China's National Health Services Survey; International Journal for Equity in Health
Health economic consequences of insulin analogues in the treatment of type 1 diabetes in Denmark; Ugeskrift for Laeger
Health economic consequences of irbesartan treatment of type 2 diabetes patients with nephropathy and hypertension in German; Deutsche Medizinische Wochenschrift
Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland; Swiss Medical Weekly
Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis; The European Journal of Health Economics
Health economics analysis of insulin aspart vs. regular human insulin in Type 2 Diabetes patients, based on observational real life evidence from general practices in Germany; Experimental and Clinical Endocrinology & Diabetes
Health economics studies assessing irbesartan use in patients with hypertension, type 2 diabetes, and microalbuminuria; Kidney International. Supplement
Health economics--what the nephrologist should know; Nephrology, Dialysis and Transplantation
Health State Utilities in Dentistry: A Review; Acta Medicinae Dentium Helvetica
Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK; Diabetic Medicine
Highly Active Antiretroviral Therapy: Pharmacoeconomic issues in the management of HIV infection; Pharmacoeconomics
How consistent is the relationship between improved glucose control and modelled health outcomes for people with type 2 diabetes mellitus? a systematic review; PharmacoEconomics
Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE Diabetes Model; Current Medical Research and Opinion
Improving life expectancy and decreasing the incidence of complications associated with type 2 diabetes: a modelling study of HbA1c targets; International Journal of Clinical Practice
Improving the availability and efficiency of appropriate urgent service provision in Tasmania: Interim evaluation of the GP Assist and the Tasmanian General Practice After-Hours Incentive Funding Model 2014-15
Increased clinical and economic advantage of proteinuric screening and intervention (PROSIT project) in type 2 diabetics; Deutsche Medizinische Wochenschrift
Insulin pumps: more consultation was needed; BMJ
Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US; Diabetes Obesity & Metabolism
Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom; Clinical Therapeutics: The International, Peer-Reviewed Journal of Drug Therapy
International Diabetes Federation: a consensus on Type 2 diabetes prevention; Diabetic Medicine
Investigating the costs of major and minor cycling crashes in Tasmania, Australia; Australian and New Zealand Journal of Public Health
Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria; Kidney International
Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis; International Journal of Clinical Practice
Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting; Current Medical Research and Opinion
Long-Term Cost-Effectiveness of Pioglitazone versus Placebo in Addition to Existing Diabetes Treatment: A US Analysis Based on PROactive; Value in Health
Low Molecular Weight Heparin for Prevention of Thromboembolism in General Surgery: A Meta-Analysis of Randomized Clinical Trials with Low Molecular Weight Heparin, Unfractionated Heparin, and Warfarin; Haemostasis
Meta-analysis in oral health care; Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics
Modeling the impact of adjustable gastric banding on survival in patients with morbid obesity; Obesity Research
Modeling the socioeconomic impact of osteoporosis-related hip fractures in Switzerland; Osteoporosis International
Modelling lifetime metabolic progression and cost effectiveness of treatment strategies for type 2 diabetes; Pharmacoeconomics
Motivations for Seeking Bariatric Surgery: The Importance of Health Professionals and Social Networks; Bariatric Surgical Practice and Patient Care
Multimorbidity and Health Care Service Utilization in the Australian Workforce; Journal of Occupational and Environmental Medicine
Multimorbidity and health-related quality of life (HRQoL) in a nationally representative population sample: implications of count versus cluster method for defining multimorbidity on HRQoL; Health and Quality of Life Outcomes
New aspects in health economic studies of prevention and treatment of osteoporosis; Expert Review of Pharmacoeconomics & Outcomes Research
Outline of a diabetes disease management model: principles and applications; Diabetes Research and Clinical Practice
Overview of costs of stroke from published, incidence-based studies spanning 16 industrialized countries; Current Medical Research and Opinion
PND10 – Cost-Effectiveness of Population Screening for Haemochromatosis In Australia: A State-Transition Model; Value in Health
PND13 – Assessing Health-State Utility Values in Australian People with Multiple Sclerosis; Value in Health
PND9 – An Australian National Cost of Illness Study For Hereditary Haemochromatosis; Value in Health
Population estimates and characteristics of Australians potentially eligible for bariatric surgery: findings from the 2011–13 Australian Health Survey; Australian Health Review
Population Screening for Hereditary Haemochromatosis in Australia: Construction and Validation of a State-Transition Cost-Effectiveness Model; PharmacoEconomics - Open
Prevention of T2DM: health economics; Diapedia. The living textbook of diabetes.
PROactive 03: Pioglitazone, type 2 diabetes and reducing macrovascular events - economic implications?; British Journal of Diabetes and Vascular Disease
PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK; Diabetic Medicine
Projected worldwide disease burden from giant cell arteritis by 2050; Journal of Rheumatology
Projection of osteoporosis-related fractures and costs in China: 2010-2050; Osteoporosis International
Psychosocial factors in adults with chronic kidney disease: characteristics of pilot participants in the Tasmanian Chronic Kidney Disease study; BMCNephrology
Psychosocial factors in chronic kidney disease: 2 year follow-up of pilot participants; ANZSN 50th Annual Scientific Meeting
Quality of life utility values for hereditary haemochromatosis in Australia; Health and Quality of Life Outcomes
Re-operations after Secondary Bariatric Surgery: a Systematic Review; Obesity Surgery
Recent trends in life expectancy for people with type 1 diabetes in Sweden; Diabetologia
Residents with mild cognitive decline and family members report health students 'enhance capacity of care' and bring 'a new breath of life' in two aged care facilities in Tasmania; Health Expectations
Residual lifetime and 10 year absolute risks of osteoporotic fractures in Chinese men and women; Current Medical Research and Opinion
Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain; Current Medical Research and Opinion
Screening for and treatment of osteoporosis: construction and validation of a state-transition microsimulation cost-effectiveness model; Osteoporosis International
Screening for osteoporosis in Chinese post-menopausal women: a health economic modelling study; Osteoporosis International
Severe hypoglycemia and mortality after cardiovascular events for Type 1 diabetic patients in Sweden; Diabetes Care
Some principles of cost-effectiveness analysis in dentistry; Acta Medicinae Dentium Helvetica
Sublingual Immunotherapy in Allergic Rhinitis and Asthma: A Review of Recent Clinical Evidence; Journal of Applied Research: in Clinical and Experimental Therapeutics
Tasmanian After-Hours Primary Care Service Innovations: A Report in Three Parts
Ten years of experience with biphasic insulin aspart 30: from drug development to the latest clinical findings
The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making; Current Medical Research and Opinion
The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes: response to Scuffham [corrected] and Carr; Diabetic Medicine
The cost-effectiveness of different management strategies for type I diabetes: a Swiss perspective; Diabetologia: Clinical and Experimental Diabetes and Metabolism
The cost-effectiveness of gemcitabine plus cisplatin chemotherapy versus mitomycin ifosfamide and cisplatin (MIP), etopiside plus cisplatin, and vinorelbine plus cisplatin in the treatment of stages III B and IV non-small cell lung cancer: An Italian perspective; Monaldi Archives for Chest Disease
The cost-effectiveness of gemcitabine plus cisplatin chemotherapy versus mitomycin ifosfamide and cisplatin (MIP), etopiside plus cisplatin, and vinorelbine plus cisplatin in the treatment of stages III B and IV non-small cell lung cancer: An Italian perspective (letter); Monaldi Archives for Chest Disease
The cost-effectiveness of interventions in diabetes: A review of published economic evaluations in the UK setting, with an eye on the future
The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy; Clinical Therapeutics: The International, Peer-Reviewed Journal of Drug Therapy
The Economic Burden of Deep Vein Thrombosis Sequelae: A Cost of Illness Analysis for Germany; Gesundheitsoekonomie und Qualitaetsmanagement
The economic impact of multiple sclerosis in Australia in 2010; Multiple Sclerosis
The impact of increasing severity of hereditary haemochromatosis on health state utility values; Value in Health
The impact of multiple sclerosis severity on health state utility values: Evidence from Australia; Multiple Sclerosis Journal
The long-term cost-effectiveness of improving alcohol abstinence with adjuvant acamprosate; Alcohol and Alcoholism
The Mt. Hood Challenge: cross-testing two diabetes simulation models; Diabetes Research and Clinical Practice
The new Australian after-hours general practice incentive payment mechanism: equity for rural general practice?; Health Policy
The relationship between return on investment and quality of study methodology in workplace health promotion programs; American Journal of Health Promotion
The support needs of patients waiting for publicly funded bariatric surgery - implications for health service planners; Clinical Obesity
Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States; Advances in Therapy: The International Journal of Drug, Device and Diagnostic Research
Treating diabetes to accepted standards of care: a 10-year projection of the estimated economic and health impact in patients with type 1 and type 2 diabetes mellitus in the United States; Clinical Therapeutics: The International, Peer-Reviewed Journal of Drug Therapy
Validation of the CORE Diabetes Model against epidemiological and clinical studies; Current Medical Research and Opinion
What are the support experiences and needs of patients who have received bariatric surgery?; Health Expectations
What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with type 2 diabetes? A projection using the CORE Diabetes Model; Current Medical Research and Opinion
What Value GP Assist? The comparative benefits of, and satisfaction with GP Assist in Residential Aged Care Facilities and General Practice in Rural and Urban Tasmania
Workplace injuries in thoroughbred racing: An analysis of insurance payments and injuries amongst jockeys in Australia from 2002 to 2010; Animals

Research Projects

AusGo-SHEMO..Let's Go! Australian Gold Standard Health Economics Model of Osteoporosis; National Health & Medical Research Council (NHMRC)
Bariatric surgery in Tasmania: investigating health service use, costs, patient outcomes and policy options; National Health & Medical Research Council (NHMRC)
Bariatric surgery in Tasmanian public hospitals: investigating health service use, costs, and policy options; Royal Hobart Hospital Research Foundation (RHHRF)
Centre of Research Excellence in Pulmonary Fibrosis; National Health & Medical Research Council (NHMRC)
Clinical Redesign of respiratory pathways in residential aged care; University of Tasmania (UTAS)
Comparison of learning focused cardiac ultrasound between self-directed/simulator and instructor/live model teaching; Australian and New Zealand College of Anaesthetists (ANZCA)
Dementia-related presentations at the Royal Hobart Hospital - A pilot program for redesigning state-wide clinical care pathways involving Tasmanian residential aged care facilities (RACFs) and their c; Royal Hobart Hospital Research Foundation (RHHRF)
DEVA MS: DEvelopment and VAlidation of a cost effectiveness simulation model for Multiple Sclerosis and implications for health policy; Multiple Sclerosis Research Australia (MSRA)
Development and validation of a health policy simulation model for type 1 diabetes; National Health & Medical Research Council (NHMRC)
Does treating multiple sclerosis alter long-term disease outcomes? a natural history study; Multiple Sclerosis Research Australia (MSRA)
Epidemiology and economic impact of injuries to jockeys in the thoroughbred racing industry; WorkCover Tasmania (WCT)
Guidance of Heart Failure Management Programs by Risk Assessment; National Health & Medical Research Council (NHMRC)
Improving care through imbedding general practitioners within residential aged care facilities; Bupa Foundation (Australia) Limited (Bupa (Aust.))
Improving health and wellbeing in the Tasmanian State Service workforce; National Health & Medical Research Council (NHMRC)
Improving prevention and early intervention for type 2 diabetes in Tasmania; University of Tasmania (UTAS)
The value of osteoporosis interventions evaluating the cost effectiveness and incorporating patients preference; National Health & Medical Research Council (NHMRC)
5th Mount Hood Challenge Conference Malmo Sweden 18-19 Sept 2011
Economic Impact of MS - 2007 cost of illness data AMSLS - PPMS sub-analysis
Economic Impact of MS in Australia Report (2018)
Evaluation of new Tasmanian general practice after hours incentive funding model and the value for money of GP Assist
GP Assist Evaluation
Provision of Health Economics consultancy service to develop a new Tasmanian GP After Hours Incentive Funding Model(s)

Research Candidate Supervision

Health Economics of Haemochromatosis, with a Focus on the Australian Setting
Health Economics of Osteoperosis-Related Fractures in Australia
Likely Impact of Coming Changes to Health Funding on New South Wales Hospitals
Managing Obesity in Tasmania
Reducing the social, personal and public burden of obesity- an economic and epidemiological analysis
Revisional Bariatric Surgery- Predictors, Outcomes and Economic Impact on Tasmanian Healthcare
The Economic Case For Workplace Health Promotion in the Tasmanian State Service- the Partnering Healthy@Work Project
The impact of job losses on the physical and mental health of Tasmanians